Latest Regulatory News

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

Renegade Exploration has identified the Myschka prospect in Canada’s Yukon as a promising Reduced Intrusion-Related Gold System, with plans underway for maiden drilling in 2026. High-grade silver, gold, and antimony samples reinforce its potential within the prolific Tombstone Gold Belt.

Cyprium Metals has secured board approval to restart copper cathode production at its Nifty Copper Complex, targeting first output by mid-2026. The plan leverages existing heap leach resources and refurbishes key processing infrastructure to generate near-term cash flow.

ReadCloud Limited reported a 5% revenue increase to $12.9 million for FY25, alongside a 109% surge in underlying EBITDA to $0.76 million, narrowing its statutory loss by 59%. Strong growth in its VET-in-Schools segment and domestic eBooks sales underpinned this improved financial performance.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

Dalrymple Bay Infrastructure Limited has reaffirmed its position as the world’s largest metallurgical coal export facility with full contracted capacity through 2028 and unveiled detailed plans for a significant terminal expansion.

Aspermont Limited's trading suspension has been lifted following a key announcement about new board appointments, signaling a fresh chapter for the media publisher.

Eagle Mountain Mining has reapplied for two cancelled exploration permits covering 12% of its Silver Mountain Project, with no expected disruption to near-term activities.

Aureka Limited has reported exceptional high-grade gold assay results from its St Arnaud Comstock Project, including a record 0.3m intercept grading 109g/t gold, extending mineralisation beyond current resource boundaries.

HeraMED has achieved a significant regulatory milestone with the Therapeutic Goods Administration upgrading its HeraBEAT fetal heart rate monitor to Class IIb, making it the only remote home-use device approved in Australia. This positions the company for a potentially lucrative expansion in the Australian maternity care market.

Island Pharmaceuticals has engaged a top Washington DC government affairs firm to accelerate its US biodefence strategy, focusing on its antiviral drug Galidesivir amid promising FDA regulatory signals.

Stealth Group Holdings has explained the late filing of a director’s interest notice as an administrative oversight, assuring no market harm occurred. The company has since strengthened its compliance controls to prevent future lapses.